Avalo Therapeutics, Inc.
NASDAQ:AVTX
Overview | Financials
| Company Name | Avalo Therapeutics, Inc. |
| Symbol | AVTX |
| Currency | USD |
| Price | 11.41 |
| Market Cap | 150,068,884 |
| Dividend Yield | 0% |
| 52-week-range | 3.39 - 16 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Garry A. Neil M.D. |
| Website | https://www.avalotx.com |
An error occurred while fetching data.
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD



